Endo Pharmaceutical Holdings Inc., Novartis sales and marketing update

In its 1Q12 earnings, Endo said it is now able to provide a "steady supply" of its crush-resistant formulation of Opana ER oxymorphone and Voltaren Gel following the January shutdown of Novartis' Li...